We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Steris (STE) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Wall Street analysts expect Steris (STE - Free Report) to post quarterly earnings of $2.32 per share in its upcoming report, which indicates a year-over-year increase of 14.3%. Revenues are expected to be $1.36 billion, up 6.2% from the year-ago quarter.
The current level reflects an upward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Steris metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Revenues- Healthcare' will reach $955.77 million. The estimate indicates a change of +6.1% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Applied Sterilization Technologies (AST)' should arrive at $266.71 million. The estimate indicates a year-over-year change of +6.8%.
The average prediction of analysts places 'Revenues- Life Sciences' at $136.48 million. The estimate points to a change of +6.2% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Healthcare Products- Service' should come in at $361.54 million. The estimate suggests a change of +5.3% year over year.
Analysts forecast 'Revenues- Healthcare Products- Capital equipment' to reach $235.39 million. The estimate points to a change of +9.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Healthcare Products- Consumables' will likely reach $355.58 million. The estimate points to a change of +3.6% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Service' will reach $634.77 million. The estimate suggests a change of +1.9% year over year.
Analysts predict that the 'Revenues- Product' will reach $714.11 million. The estimate indicates a change of +8.8% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Life Sciences- Service' of $34.87 million. The estimate indicates a year-over-year change of +8.3%.
The consensus estimate for 'Revenues- Life Sciences- Consumables' stands at $70.04 million. The estimate indicates a change of +0.3% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Life Sciences- Capital equipment' reaching $30.95 million. The estimate points to a change of +16.9% from the year-ago quarter.
Analysts expect 'Operating income / (loss)- Healthcare' to come in at $225.54 million. The estimate is in contrast to the year-ago figure of $216.89 million.
Over the past month, shares of Steris have returned -4.5% versus the Zacks S&P 500 composite's +0.6% change. Currently, STE carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Steris (STE) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Wall Street analysts expect Steris (STE - Free Report) to post quarterly earnings of $2.32 per share in its upcoming report, which indicates a year-over-year increase of 14.3%. Revenues are expected to be $1.36 billion, up 6.2% from the year-ago quarter.
The current level reflects an upward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Steris metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Revenues- Healthcare' will reach $955.77 million. The estimate indicates a change of +6.1% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Applied Sterilization Technologies (AST)' should arrive at $266.71 million. The estimate indicates a year-over-year change of +6.8%.
The average prediction of analysts places 'Revenues- Life Sciences' at $136.48 million. The estimate points to a change of +6.2% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Healthcare Products- Service' should come in at $361.54 million. The estimate suggests a change of +5.3% year over year.
Analysts forecast 'Revenues- Healthcare Products- Capital equipment' to reach $235.39 million. The estimate points to a change of +9.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Healthcare Products- Consumables' will likely reach $355.58 million. The estimate points to a change of +3.6% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Service' will reach $634.77 million. The estimate suggests a change of +1.9% year over year.
Analysts predict that the 'Revenues- Product' will reach $714.11 million. The estimate indicates a change of +8.8% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Life Sciences- Service' of $34.87 million. The estimate indicates a year-over-year change of +8.3%.
The consensus estimate for 'Revenues- Life Sciences- Consumables' stands at $70.04 million. The estimate indicates a change of +0.3% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Life Sciences- Capital equipment' reaching $30.95 million. The estimate points to a change of +16.9% from the year-ago quarter.
Analysts expect 'Operating income / (loss)- Healthcare' to come in at $225.54 million. The estimate is in contrast to the year-ago figure of $216.89 million.
View all Key Company Metrics for Steris here>>>Over the past month, shares of Steris have returned -4.5% versus the Zacks S&P 500 composite's +0.6% change. Currently, STE carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .